...Inc. (HKEX:9926) plus chemotherapy met the primary endpoint for first-line squamous non-small cell lung cancer.FDA denies Tricida...
...VCs and KOSDAQ-listed companies.TARGETSPD-1 (PDCD1; CD279) - Programmed cell death 1 Jeff Cranmer Venrock Artiva Biotherapeutics Roivant Sciences Silicon Therapeutics BridgeBio Pharma Tricida LISCure...

...checkpoint targets, into a late-stage PD-1/PD-L1 combination study.Tricida cuts staff with accelerated approval for veverimer ‘unlikely’Tricida Inc....
...company, the agency also would require data on renal disease progression to support accelerated approval. Tricida...
...– Transient receptor potential cation channel subfamily C member 6 BC Staff aducanumab (BIIB037) Eisai Co. Ltd. Boehringer Ingelheim Arcus Biosciences Tricida BI...

...overall survival of 6.4 months, compared with 6.3 months for physician’s choice treatment (p=0.33).FDA rebuffs Tricida’s...
...and “the demonstrated effect size would be reasonably likely to predict clinical benefit.” Shares of Tricida fell...
...sodium (ON 01910.Na, estybon, iv rigosertib) veverimer (TRC101) samidorphan/olanzapine (ALKS 3831) China National Biotech Group (Sinopharm)-COVID-19-unknown Novartis AG Odonate Therapeutics Inc. Tricida Inc. Alkermes...

...of the U.S. innovative medicines unit of Bristol Myers Squibb Co. (NYSE:BMY). Renal disease play Tricida Inc....
...promoted Bobbi Coffin to chief growth officer from chief marketing officer. Robin Sawka, BioCentury Staff BioCentury Staff Genmab A/S Tricida Inc. Akcea...

...of Caraway; he co-founded the company and will remain on the board. Renal disease play Tricida Inc....
...Hongjiang Li, Staff Writers Xenikos B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Rheostat Therapeutics Tricida Inc. Revance...

...U.S. as early as November 20, 2023; Pfizer plans to launch the drug that year. Tricida’s...
...Priority Review FDA accepted and granted Priority Review to an NDA for veverimer (TRC101) from Tricida Inc....
...to anti-inflammatory franchise" ). BioCentury Staff Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Humira, adalimumab (D2E7) Otezla, apremilast (CC-10004) Janssen Johnson & Johnson Pfizer Inc. Tricida Inc. Bristol-Myers...

...A) 4/9/19 $10.0 NA $10.6 NA Sangamo Therapeutics Inc. (NASDAQ:SGMO) 4/7/19 $145.5 $1,321.6 $1,242.4 -6% Tricida Inc....

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine Treat recurrent high-grade glioma Phase III final data YE19 Tricida Inc....

...new listing, from NGM, and $398.5 million raised across three follow-ons from Sangamo Therapeutics Inc., Tricida Inc....
...NGM282, is due to begin Phase IIb testing in mid-2019 to treat NASH. Sangamo and Tricida...

...Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts...
...I/II Readout for Hemophilia A Gene Therapy" ). Sangamo lost $0.89 to $12.14 on Thursday. Tricida Inc....
...GI tract (see "Tricida Gains on Long-Term Phase III Data for Metabolic Acidosis Therapy" ). Tricida...